Skip to main content
. 2022 Aug 8;8:353. doi: 10.1038/s41420-022-01146-7

Fig. 7. Keap1 Cys151S mutation abolishes Cpd16-induced Nrf2 cascade activation and osteoblasts cytoprotection.

Fig. 7

Stable primary human osteoblasts with Cys151S Keap1 (“Keap1-C151S”) or Vector were treated with Cpd16 (25 μM), listed proteins and genes were measured (AC). Alternatively, the primary human osteoblasts were pretreated with Cpd16 (25 μM) for 2 h, followed by H2O2 (400 μM) stimulation, and cell viability, apoptosis, and necrosis were tested by CCK-8 (D), TUNEL-nuclei staining (E), and LDH releasing F assays, respectively. #P < 0.05.

HHS Vulnerability Disclosure